These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 30900800)
21. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310 [TBL] [Abstract][Full Text] [Related]
22. Hydroxyurea in very young children with sickle cell anemia is not a cure-all. Powars DR J Pediatr; 2001 Dec; 139(6):763-4. PubMed ID: 11743496 [No Abstract] [Full Text] [Related]
23. Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia. Karkoska K; Quinn CT; Niss O; Pfeiffer A; Dong M; Vinks AA; McGann PT Am J Hematol; 2021 May; 96(5):538-544. PubMed ID: 33534136 [TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea use in patients with sickle cell disease in a Medicaid population. Ritho J; Liu H; Hartzema AG; Lottenberg R Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530 [No Abstract] [Full Text] [Related]
25. The Impact of Sickle Cell Anemia and Mental Health Diagnoses on Healthcare Use and Preventive Care among Children Enrolled in Medicaid, 2005-2012. Gondhi JP; Dombkowski KJ; Scott EL; Reeves SL J Pediatr; 2020 Sep; 224():79-86.e2. PubMed ID: 32446724 [TBL] [Abstract][Full Text] [Related]
26. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184 [TBL] [Abstract][Full Text] [Related]
27. The role of hydroxyurea in sickle cell disease. Halsey C; Roberts IA Br J Haematol; 2003 Jan; 120(2):177-86. PubMed ID: 12542474 [No Abstract] [Full Text] [Related]
28. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature]. Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961 [TBL] [Abstract][Full Text] [Related]
29. Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort. Quarmyne MO; Dong W; Theodore R; Anand S; Barry V; Adisa O; Buchanan ID; Bost J; Brown RC; Joiner CH; Lane PA Am J Hematol; 2017 Jan; 92(1):77-81. PubMed ID: 27761932 [TBL] [Abstract][Full Text] [Related]
30. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898 [TBL] [Abstract][Full Text] [Related]
31. Sickle cell patients find a brand New World. Noonan SS N J Med; 1999 Aug; 96(8):23-5. PubMed ID: 10457727 [TBL] [Abstract][Full Text] [Related]
32. Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea. Singh SA; Koumbourlis AC; Aygun B Pediatr Blood Cancer; 2008 Jun; 50(6):1258-60. PubMed ID: 18293380 [TBL] [Abstract][Full Text] [Related]
33. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732 [TBL] [Abstract][Full Text] [Related]
34. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503 [TBL] [Abstract][Full Text] [Related]
35. Adherence to hydroxyurea therapy in children with sickle cell anemia. Thornburg CD; Calatroni A; Telen M; Kemper AR J Pediatr; 2010 Mar; 156(3):415-9. PubMed ID: 19880135 [TBL] [Abstract][Full Text] [Related]
36. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea. Tripathi A; Jerrell JM; Stallworth JR Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765 [TBL] [Abstract][Full Text] [Related]
37. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria. Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630 [No Abstract] [Full Text] [Related]
38. Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease. Fung EB; Barden EM; Kawchak DA; Zemel BS; Ohene-Frempong K; Stallings VA J Pediatr Hematol Oncol; 2001 Dec; 23(9):604-8. PubMed ID: 11902305 [TBL] [Abstract][Full Text] [Related]
39. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922 [TBL] [Abstract][Full Text] [Related]
40. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Wang WC; Oyeku SO; Luo Z; Boulet SL; Miller ST; Casella JF; Fish B; Thompson BW; Grosse SD; Pediatrics; 2013 Oct; 132(4):677-83. PubMed ID: 23999955 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]